CFCareForward Program

CFCareForward provides financial, nutritional, and educational support for patients with cystic fibrosis (CF)

CFCareForward provides:

  • Prescription savings*
  • Nutritional supplements and multivitamins delivered at no charge
  • Access to informational and educational materials
  • Quick and easy enrollment at CFCareForwardEnrollment.com

Financial assistance programs offer patients more
affordable treatment

Most patients using CFCareForward co-pay will PAY $0 for CREON2*

Get financial assistance using the CREON Co-pay Card
  • Eligible CREON patients PAY $0 when commercial prescription cost is $50 or less, or as little as $5 when prescription cost is $55 or more
  • CREON CFCareForward can be used for commercial co-pay, co-insurance, and high-deductible plans*
  • Remember to give your patients a CREON co-pay card along with their prescription. If you need CREON co-pay cards for your office, please contact a representative

Source: Amundsen Group, Q2 2014-Q1 2015, 2015.

*Eligibility: Available to patients with commercial prescription insurance coverage for CREON. Co-pay assistance program and nutritional and multivitamin products are not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

AbbVie’s Patient Assistance Foundation provides medicines at no cost to qualified patients. Learn More


A variety of products for nutritional and vitamin support
at every age

Get nutrional supplements for patients using CREON CFCareForward

Offering choices from Abbott Nutrition, including Similac®, PediaSure®, Ensure®, ZonePerfect® Bars, EAS®, and much more

  • Products designed specifically for patients with CF of all ages
  • Multivitamins in liquid, chewable, and softgel formulations

For CFCareForward participants filling CREON prescriptions. Subject to availability.


Patient education resources and materials

Provide patient resources about CREON and EPI
  • Contact a representative to order patient starter kits, brochures, and pamphlets for your office staff to distribute to patients
  • Encourage patients or caregivers to register in CFCareForward to get information about EPI and CREON, plus educational emails about:
    • Savings opportunities
    • Facts about EPI
    • Getting started on CREON
    • Tracking progress
Request patient starter kits, product samples, and more

Request patient starter kits, product samples, and more

Contact a Rep
Use the dosing calculator to help determine the proper dosage of CREON® (pancrelipase)

Determine an appropriate per-meal dose for your patients

Use Dosing Guide

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. References:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.
  3. Data on file. North Chicago, IL: AbbVie Inc.

back to top #tbd